,39–41 Increased mTORC1 activity has been shown in FCD type II and HME specimens from patients with somatic mutations in mTOR pathway activating genes (MTOR, PIK3CA, AKT3 and RHEB).9 This evidence concerns the gene AKT3 and isolated focal cortical dysplasia type II.